Molecular Analysis of c-Kit and PDGFRA in GISTs Diagnosed by EUS

Ana L. Gomes, BSc,1 Ricardo H. Bardales, MD,2* Fernanda Milanezi, MD,1,3 Rui M. Reis, PhD,1 and Fernando Schmitt, MD, PhD1,3,4

Key Words: Endoscopic ultrasound-guided fine-needle aspiration; c-Kit; Platelet-derived growth factor-α; PDGFRA; Gastrointestinal stromal tumor; GIST; Mutations

DOI: 10.1309/M1EC8JE9ACAMJACU

Abstract

Gastrointestinal stromal tumors (GISTs) are characterized by overexpression and mutations of c-Kit. Approximately 80% of c-Kit mutations occur in exon 11, being a response factor to imatinib (Gleevec) therapy. Mutations of platelet-derived growth factor receptor-α (PDGFRA) are observed in a subset of GISTs lacking c-Kit mutations.

We aimed to assess whether c-Kit and PDGFRA mutation analysis of GISTs obtained by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) could be routinely performed. Mutation analysis of c-Kit hotspot exons (9, 11, 13, and 17) and PDGFRA hotspot exons (12 and 18) was performed in aspirates of 33 GISTs and 18 non-GIST mesenchymal tumors.

Of the GIST cases, 19 (58%) of 33 contained a mutation in exon 11, 1 (3%) in exon 9, and none in exons 13 and 17. No activating c-Kit mutations were identified in non-GIST cases. No PDGFRA mutation was detected.

Mutation analysis is possible in these FNA cell blocks and can assist in the diagnosis and therapeutic decisions in GIST cases.

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract, with an annual incidence of 10 to 20 cases per million.1 GISTs are rarely found outside the gastrointestinal tract, being most commonly found in the stomach (40%-70%), small intestine (20%-50%), colon and rectum (5%-15%), and esophagus (<2%).2 These tumors are thought to arise from interstitial cells of Cajal owing to their similar positive immunoreactivity for CD34 and CD117 (c-Kit), and to their lack of immunoreactivity for desmin and S-100 protein. Interstitial cells of Cajal are spindle-shaped cells located throughout the gastrointestinal tract. They are specialized cells of the enteric nervous system forming a network in the myenteric plexus layer, which primarily controls gastrointestinal tract motility.3

Before 1998, almost all GISTs were misdiagnosed as smooth muscle tumors such as leiomyomas, leiomyosarcomas, or leiomyoblastomas.4,5 In 1998, Hirota et al6 described the expression of c-Kit protein as an incontestable feature of GISTs, further separating them from other gastrointestinal mesenchymal tumors. At present, GIST is considered to be a specific category different from true smooth muscle tumors and neurogenic tumors.7

c-Kit belongs to the class III receptor tyrosine kinases (RTKs), together with platelet-derived growth factor receptor-α (PDGFRA), colony-stimulating factor-1 receptor (CSF-1-R), vascular endothelial growth factor receptors 1 and 2 (Flt-1 and Flk-1, respectively), Flk-2, and Flt-4. The RTKs are characterized by the presence of an extracellular domain, a transmembrane domain, a juxtamembrane domain, and an intracellular domain where the 2 kinase domains are lodged.8 Activation of c-Kit occurs when by the binding of stem cell factor, the receptor homodimerizes and experiences conformational
transformations that lead to the activation of the kinase domains. These, in turn, transphosphorylate the tyrosine residues of the opposing homodimerized receptor, allowing its association with substrates of various kinds.8 Like the majority of RTKs, c-Kit has been attributed many physiologic functions such as cell survival, proliferation, differentiation, adhesion, and apoptosis by signaling through the MAP kinase, PI3-kinase, and JAK/STAT pathways.9 c-Kit signaling is essential for normal erythropoiesis, lymphopoiesis, gametogenesis, and melanogenesis and for the correct development and function of mast cells.10 A dysfunctional activation of this RTK, therefore, has been involved in diverse neoplasias such as mastocytosis/mast cell leukemia,11 germ cell tumors,12 small cell lung carcinoma,13 acute myeloid leukemia,14 neuroblastoma,15 melanoma,16 ovarian carcinoma,17 and breast carcinoma,18 besides GISTs.2,3,7,8

Mutations of the c-Kit oncogene are the major genetic alterations in GISTs. There is a broad spectrum of c-Kit mutations in GISTs, ranging from 30% to 90%, and c-Kit status can constitute a prognostic factor for survival.19 Most of the mutations are located in the juxtamembrane domain (exon 11), followed by the extracellular domain (exon 9), and seldom are in the kinase domains (exon 13 and 17). Recently, Heinrich et al20 showed that about 35% of GISTs lacking c-Kit mutations have intragenic activation mutations in PDGFRA, the most common, located in exons 12, 14, and 18. Mutations of c-Kit and PDGFRA seem to be mutually exclusive oncogenic events in GISTs.20

Until recently, the prognosis of patients with GISTs was poor owing to its frequent recurrence and resistance to chemotherapy and radiotherapy regimens.21 The development and current treatment with specific RTK inhibitors is changing this scenario. Imatinib mesylate (Gleevec) is a selective inhibitor of RTKs; by competing with the adenosine triphosphate for its binding site, preventing further phosphorylation of signaling molecules downstream of the receptor, it is responsible for abnormal viability and proliferation signals in these cells.22 Several studies have linked different responses to the drug with c-Kit alterations. In particular, tumors harboring exon 11 c-Kit mutations are more likely to respond to imatinib therapy than those with exon 9 c-Kit mutations or no detectable mutation.23 On the other hand, some mutations, such as D816V, are linked to imatinib response.23 Currently, imatinib is used for the treatment of patients with c-Kit (CD117)-positive GIST with unresectable and/or metastatic malignant tumor.24 Besides imatinib, another RTK inhibitor, sunitinib (Sutent), has been recently approved for the treatment of patients with GIST whose disease has progressed or who are unable to tolerate treatment with imatinib.25

It is a fact that obtaining an accurate diagnosis is of utmost importance for correct treatment; an earlier diagnosis is crucial for prompt therapy. Endoscopic ultrasound–guided fine-needle aspiration (EUS-FNA) biopsy has been increasingly used for the assessment of diverse intra-abdominal and intrathoracic tumors.26,27

EUS-FNA biopsy not only allows for a meticulous representation of extramural and intramural structures of the gastrointestinal tract but also permits tissue sampling from masses in these locations.28,29 In the present study, we aimed to perform molecular analysis of c-Kit and PDGFRA genes in formalin-fixed, paraffin-embedded cell blocks obtained by EUS-FNA biopsy from GISTs and non-GISTs. The feasibility of such analysis would lead to a more precise diagnosis and therapeutic decision in routine management of patients with GISTs (particularly patients with recurrent or imatinib-resistant tumors).

Materials and Methods

Tissue Samples

Between January 2000 and December 2005, 85 patients with intramural gastrointestinal mesenchymal tumors were diagnosed by EUS-FNA biopsy at Hennepin County Medical Center, Minneapolis, MN. These tumors were preclassified by the pathology department as 48 GISTs, 5 schwannomas, 27 leiomyomas, and 5 nonspecified spindle cell tumors.

Original classification of the tumors was based on immunocytochemical analysis for GIST (CD117+/CD34+), schwannoma (S-100 protein+/CD117–), and leiomyoma (actin+/desmin+/CD117–). Case selection for the study was based on specimen availability for molecular and immunocytochemical analysis. Cell blocks of the initial 85 cases were obtained; however, molecular analysis and complete repeated immunocytochemical analysis were possible in 49 cases, and in 2 cases, it was possible to perform only molecular analysis. Original and repeated immunocytochemical results were compared. Table II lists the 51 cases, which included 33 GISTs, 14 leiomyomas, and 4 schwannomas. The mean age of patients was 62.5 years (range, 26-92 years). Of the patients, 20 (39%) were women and 31 (61%) were men. Topographically, 12 tumors (24%) were located in the esophagus, 35 (69%) were gastric, and 4 (8%) were located in the small intestine. The mean tumor size documented by EUS was 33.9 mm (range, 11-80 mm). The clinicopathologic features of the cases are summarized in Table 1.

c-Kit Immunocytochemical Studies

Immunocytochemical studies of the 51 cases were performed in material obtained from cell blocks. The procedure was performed according to streptavidin-biotin-peroxidase complex principle, using rabbit polyclonal antihuman antibodies raised against c-Kit (clone A 4502, dilution 1:50; DAKO, Carpinteria, CA), as previously described.30 Briefly, deparaffinized and rehydrated slides were subjected to 10

© American Society for Clinical Pathology
minutes’ incubation in 3% hydrogen peroxide in methanol to inhibit endogenous peroxidase. No antigen retrieval was used. After incubation with the primary antibody at room temperature for 2 hours, the secondary biotinylated goat anti–polyvalent antibody was applied for 10 minutes, followed by incubation with streptavidin-peroxidase complex. The immune reaction was visualized with 3,3’-diaminobenzidine (DAB) as the chromogen (Ultravision Detection System Anti-polyvalent, HRP/DAB; Lab Vision, Fremont, CA). Appropriate positive and negative control samples were included in each run: a case of gastrointestinal stromal tumor with previously characterized c-Kit overexpression was used as a positive control sample. For negative control samples, primary antibodies were omitted. All sections were counterstained with hematoxylin.

### DNA Isolation

Selected areas that contained at least 85% of tumor tissue were microdissected under microscopic view and collected.
into a microfuge tube using a sterile needle (Neolus, 25 gauge, 0.5 mm, Terumo, Tokyo, Japan). The dissected tissue was deparaffinized by a serial extraction with xylol and ethanol (100%-70%-50%) and allowed to air dry. DNA was extracted using the QIAamp DNA Micro Kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. DNA samples were stored at –20°C for further analysis.

**c-Kit Mutation Analysis**

*c-Kit* mutation analysis was performed as previously described. DNA was subjected to polymerase chain reaction (PCR) amplifications of exons 9, 11, 13, and 17 of the *c-Kit* gene. Briefly, the PCR reaction was carried out in a final volume of 25 µL under the following conditions: 1× Buffer (Bioron, Ludwigshafen, Germany); 1.5 mmol/L of magnesium chloride (Bioron); 200 µmol/L of deoxyribonucleotide triphosphates (dNTPs; Fermentas, Burlington, Canada); 0.5 µmol/L of primers (DNA Technology, Aarhus, Denmark; previously described by Corless et al), and 1 U of Super Hot Taq Polymerase (Bioron).

PCR amplification was followed by single-strand conformation polymorphism (SSCP) analysis of exons 9, 13, and 17 of *c-Kit* in a 1× mutation detection enhancement gel (Cambrex, North Brunswick, NJ), with 6% glycerol added in the exon 13 analysis. Twenty microliters of the PCR product were incubated at 95°C for 10 minutes with an equal volume of formamide loading buffer (98% formamide, 10 mmol/L of EDTA, and 1 mg/mL of bromophenol blue and xylene cyanol). SSCP gels were run at 20°C for exons 9, 13, and 17. Samples with an SSCP pattern different from the normal pattern were directly sequenced. Direct sequencing of exons 9, 13; and 5'-ACACGGCTTTACCTCCAATG-3' (reverse, exon 11); 5'-CATCAGTTTGCCAGTTGTGC-3' (forward, exon 11); 5'-ACCCAAAAAGGTGACATGGA-3' (reverse, exon 9); 5'AGCCAGGGCTTTTGTTTTCT-3' (forward, exon 9); 5'-CTCTGGTGCACTGGGACTTT-3' (forward, exon 12); and 5'-AAAGGGAGTCTTGGGAGGTT-3' (reverse, exon 12). Direct sequencing results were confirmed with a new PCR amplification and direct sequencing procedure.

**Statistical Analysis**

Clinical and molecular data were analyzed with StatView for Windows, version 5.0. A P value less than .05 was considered significant.

**Results**

**Immunocytochemical Results**

All non-GIST cases were immunonegative for CD117 (*c-Kit*). The tumor cells were immunoreactive for S-100 protein or actin and desmin in all schwannoma and leiomyoma cases, respectively (data not shown). In 2 cases (cases 23 and 27), the immunostaining was not interpretable owing to technical artifacts (Table 1). Immunoreactivity for CD117 was detected in a majority of the remaining 31 tumors preclassified as GISTs. In 77% (24/31) of GIST tumors, CD117 positivity was strongly present at the membrane and diffuse in the cytoplasm.

**PDGFRα Mutation Analysis**

Tumors with a wild-type *c-Kit* gene were further screened for hotspot *PDGFRα* mutations (exons 12 and 18) as previously described. Briefly, the PCR reaction was carried out in a final volume of 25 µL, under the following conditions: 1× Buffer (Bioron); 1.5 mmol/L of magnesium chloride (Bioron); 200 µmol/L of dNTPs (Fermentas); 0.5 µmol/L of primers (DNA Technology; previously described by Corless et al), and 1 U of Super Hot Taq Polymerase (Bioron). PCR was followed by direct sequencing. Direct sequencing of both exons was done with the following internal primer set: 5'-CTCTGGTGCACTGGGACTTT-3' (forward, exon 12); 5'-AAAGGGAGTCTTGGGAGGTT-3' (reverse, exon 12). Direct sequencing results were confirmed with a new PCR amplification and direct sequencing procedure.

**PDGFRα Mutation Screening**

No *PDGFRα* activating mutations were detected in the *c-Kit* wild-type–bearing tumors. Mutational analysis of exon 18 showed the presence of a base insertion in the intron preceding exon 18, ie, IVS18-50insA. Mutation analysis of exon 12
showed the presence of a homozygous substitution of an adenine for a guanine (polymorphism R) in the third position of the codon coding for proline 567. All cases analyzed showed both polymorphisms.

**Statistical Analysis**

Tumor type was statistically correlated with patient age \((P = .022)\); the median age for patients with GISTs was 67.8 years; with leiomyoma, 55.8 years; and with schwannoma, 43.0 years. Statistical significance was maintained when comparing GISTs with other tumors \((P = .013)\).

Tumor type was also statistically correlated with common gastric topography \((P < .0001)\), CD117 expression \((P < .001)\), and presence of a \(c\)-Kit mutation \((P = .0105)\). All cases with mutated \(c\)-Kit were preclassified as GIST tumors. For GIST cases, expression of CD117 was correlated with presence or

### Table 2
**Amino Acid Sequence of Exon 11 of Wild-Type and Mutated \(c\) Protein**

<table>
<thead>
<tr>
<th>Case No.</th>
<th>550</th>
<th>560</th>
<th>570</th>
<th>580</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild type</td>
<td>KPMYEVQWKV</td>
<td>VEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>1</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQPYPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>2</td>
<td>KPMNEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQPYNPD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>3</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQPYPD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>4</td>
<td>KPMYEVQWKV</td>
<td>VEEINGNNY</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>5</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>6</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>7</td>
<td>KPMYEVQWKV</td>
<td>VEEINGNNY</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>8</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>9</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>10</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>11</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>12</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>13</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>14</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>15</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>16</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>17</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>18</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>19</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>20</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>21</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>22</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>23</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>24</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>25</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>26</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>27</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>28</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>29</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>30</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>31</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>32</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
<tr>
<td>33</td>
<td>KPMYEVQWKV</td>
<td>DEEINGNYV</td>
<td>YIDPQLPYD</td>
<td>HKWEPFRNRL</td>
</tr>
</tbody>
</table>

* Underscore indicates deleted amino acid residues.
Gomes et al / C-Kit and PDGFRA in FNA of GIST

absence of c-Kit mutations ($P < .003$). All immunonegative GIST cases had wild-type c-Kit, and all cases with mutated c-Kit expressed CD117.

No other statistical significance was obtained for any other variables.

Discussion

GISTs comprise a broad clinical spectrum from benign, incidentally detected intramural nodules to severe, locally aggressive, or metastatic malignant tumors. Because they are generally resistant to chemotherapy and radiotherapy, the preferred treatment modality for GIST is surgery. The intensive cancer research during the last decade demonstrated the fundamental role of RTK, in particular kit in the pathogenesis of GIST. c-Kit has become more than just a diagnostic marker; it is actually of great value for therapeutic approaches given the development of RTK inhibitors such as imatinib.

In the present study, we have shown that 77% of GISTs strongly and diffusely express c-Kit, irrespective of tumor topography or patient age or sex. Although several studies indicate that 95% to 100% of GIST cases express c-Kit, lower expression levels have been reported in Australian (78%) and Scandinavian studies (85%). Such differences in protein expression levels are probably due to distinct methods and population diversity. We identified c-Kit mutations in 61% of GIST cases, in accordance with previously published ranges (30%-90%).

Nearly 95% (19/20) of c-Kit–mutant tumors carried exon 11 mutations. In 84% of these cases (16/19), mutations were clustered in the region between codons 550 and 561, known to be the most frequently altered section of exon 11, with 31% affecting codons 557 or 558. These 2 codons are reported to be associated with the metastatic behavior of GISTs.

Besides having detected a single case bearing a known duplication in exon 9 (502dup503), no mutations were found in exon 13 or 17 (kinase domains). Interestingly, although reported to be associated with an intestinal localization, the GIST case bearing a c-Kit exon 9 mutation had a gastric location. Indeed, 88% of our FNA-GIST series was topographically classified as gastric. No colonic GISTs were identified in this study, and this is most likely because most EUSs were done in the upper gastrointestinal tract.

Even though it is well accepted that approximately 20% of c-Kit wild-type–bearing GISTs harbor PDGFRA mutations, none was detected in the present series. More interesting is that despite the reported association between PDGFRA mutants and gastric location and despite the location of more than 85% of c-Kit wild-type–bearing GISTs in the stomach, no genetic alteration in PDGFRA exon 12 or 18 was detected. Although methodological reasons cannot be ruled out, our experience has shown a frequency of 31% of PDGFRA mutations in Portuguese c-Kit wild-type GISTs (personal observation).

Table 3
Amino Acid Sequence of Exon 9 of Wild-Type and Mutated c-Kit Protein

<table>
<thead>
<tr>
<th></th>
<th>495</th>
<th>600</th>
<th>510</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild type</td>
<td>N DVGK</td>
<td>TSAYFNFAFK</td>
<td>GN</td>
</tr>
<tr>
<td>Case 32</td>
<td>N DVGK</td>
<td>TSAYAYFNF A</td>
<td>FK</td>
</tr>
</tbody>
</table>

Discussion

GISTs comprise a broad clinical spectrum from benign, incidentally detected intramural nodules to severe, locally aggressive, or metastatic malignant tumors. Because they are generally resistant to chemotherapy and radiotherapy, the preferred treatment modality for GIST is surgery. The intensive cancer research during the last decade demonstrated the fundamental role of RTK, in particular kit in the pathogenesis of GIST. c-Kit has become more than just a diagnostic marker; it is actually of great value for therapeutic approaches given the development of RTK inhibitors such as imatinib.

In the present study, we have shown that 77% of GISTs strongly and diffusely express c-Kit, irrespective of tumor topography or patient age or sex. Although several studies indicate that 95% to 100% of GIST cases express c-Kit, lower expression levels have been reported in Australian (78%) and Scandinavian studies (85%). Such differences in protein expression levels are probably due to distinct methods and population diversity. We identified c-Kit mutations in 61% of GIST cases, in accordance with previously published ranges (30%-90%).

Nearly 95% (19/20) of c-Kit–mutant tumors carried exon 11 mutations. In 84% of these cases (16/19), mutations were clustered in the region between codons 550 and 561, known to be the most frequently altered section of exon 11, with 31% affecting codons 557 or 558. These 2 codons are reported to be associated with the metastatic behavior of GISTs.

Besides having detected a single case bearing a known duplication in exon 9 (502dup503), no mutations were found in exon 13 or 17 (kinase domains). Interestingly, although reported to be associated with an intestinal localization, the GIST case bearing a c-Kit exon 9 mutation had a gastric location. Indeed, 88% of our FNA-GIST series was topographically classified as gastric. No colonic GISTs were identified in this study, and this is most likely because most EUSs were done in the upper gastrointestinal tract.

Even though it is well accepted that approximately 20% of c-Kit wild-type–bearing GISTs harbor PDGFRA mutations, none was detected in the present series. More interesting is that despite the reported association between PDGFRA mutants and gastric location and despite the location of more than 85% of c-Kit wild-type–bearing GISTs in the stomach, no genetic alteration in PDGFRA exon 12 or 18 was detected. Although methodological reasons cannot be ruled out, our experience has shown a frequency of 31% of PDGFRA mutations in Portuguese c-Kit wild-type GISTs (personal observation).
Imatinib was initially designed to inhibit the bcr/abl fusion kinase protein in chronic myeloid leukemia and was later discovered to be effective against GISTs with c-Kit and PDGFRA mutations. Response to imatinib therapy is dependent on the presence of activating mutations in either class III RTK; however, some patients have tumors with imatinib-resistant mutations. Specifically, mutations affecting the juxtamembrane domain (exon 11; partial response in 83.5%) or the extracellular domain (exon 9; partial response in 47.8%) are responsive to imatinib, whereas mutations in the other 2 c-Kit hotspots are predominantly resistant, ie, V654A and W670I (in kinase domain 1, exon 13) and D816V and T823D (in kinase domain 2, exon 17).19,37,38

Regarding the PDGFRA mutation, the majority of alterations affecting codon 842 in exon 18 (corresponding to exon 17 of c-Kit) are known to be imatinib-resistant.1,32 Even so, approximately 40% of patients with GISTs lack activating mutations in either RTK, and most are consequently not responsive to imatinib.1,32 In early 2006, the US Food and Drug Administration approved a new RTK inhibitor, sunitinib (Sutent) for the treatment of patients with GIST whose disease has progressed or who are unable to tolerate treatment with imatinib.25 This recent RTK inhibitor has opened new doors to other RTK-overexpressing tumors in view of the fact that positive therapy responses are obtained in the presence of the wild-type RTK or the previously described imatinib-resistant mutants.39 Progress has made it necessary to accurately define the type of mutation present in these tumors.

EUS-FNA, a less costly, less risky, and less invasive strategy than several other options, is an increasingly used procedure for the diagnosis of gastrointestinal tumors. However, most studies comprise small series and lack molecular analysis of the key pathogenetic oncogenes (c-Kit and PDGFRA).26,28,40-42 In the present study, we have shown that GISTs could be diagnosed preoperatively on EUS-FNA specimens. In addition to immunocytochemical studies, molecular analysis can be done on formalin-fixed, paraffin-embedded cell-block material obtained from these aspirates, avoiding more invasive diagnostic procedures to obtain a tissue diagnosis.

Nowadays, with 2 RTK inhibitors available, there is an imperative need for redefining GIST diagnosis and including molecular analysis of c-Kit and PDGFRA in the current diagnostic protocol so as to better and more quickly establish the specific therapeutic approach to use for a particular patient. We are unquestionably taking one step forward in the diagnosis of GIST by making the molecular analysis routinely feasible with a small sample.

References


38. Frost MJ, Ferrao PT, Hughes TP, et al. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther. 2002;1:1115-1124.


